IP Library Granted Patent US 11,357,857
Granted Patent B2
US 11,357,857 · App. 15/896,374 · Granted Jun 14, 2022

Excipient compounds for protein processing

Inventors: David S. Soane (Palm Beach, FL); Philip Wuthrich (Watertown, MA); Robert P. Mahoney (Newbury, MA); Mark Moody (Concord, MA); Daniel G. Greene (Belmont, MA); Neil L. Schauer (Milford, MA)
Assignee: Comera Life Sciences, Inc.
A61K47/22A61K9/0019A61K38/1793A61K38/1816A61K38/193A61K38/385A61K38/47A61K39/395A61K39/39591A61K47/02A61K47/12A61K47/18A61K47/183A61K47/20A61K47/24A61K47/42A61K47/60C07K16/00C07K16/22C07K16/32C12N9/2462C12N9/96C12Y302/01017
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,357,857
App. No.
15/896,374
Granted
Jun 14, 2022
Kind
B2
Abstract

Disclosed herein are methods for improving a parameter of a protein-related process comprising providing a viscosity-reducing excipient compound selected from the group consisting of hindered amines, anionic aromatics, functionalized amino acids, oligopeptides, short-chain organic acids, and low molecular weight aliphatic polyacids, and adding a viscosity-reducing amount of the viscosity-reducing excipient compound to a carrier solution for the protein-related process, wherein the carrier solution contains a protein of interest, and carrier solutions comprising a liquid medium in which is dissolved a protein of interest, and a viscosity-reducing excipient, wherein the viscosity of the carrier solution has a lower viscosity that that of a control solution that is substantially similar to the carrier solution except for the presence of the viscosity-reducing excipient.

Claims (29)

1. A method of improving a parameter of a filtration process, wherein the filtration process is the filtration of a protein solution, the method comprising:

preparing a caffeine-containing protein solution by adding a viscosity-reducing amount of caffeine to a carrier solution, and adding the protein to the carrier solution before or after the addition of the caffeine, and

filtering the caffeine-containing protein solution;

wherein the improved parameter is selected from the group consisting of:

i. a faster filtration rate than the filtration rate of a control solution;

ii. production of a lower amount of aggregated protein than the amount of aggregated protein produced by a control filtration process;

iii. a higher mass transfer efficiency than the mass transfer efficiency of the control filtration process; and

iv. a higher concentration or a higher yield of the protein than the concentration or yield of the protein produced by the control filtration process;

wherein the control solution does not contain caffeine but is otherwise identical to the caffeine-containing protein solution, and wherein the control filtration process is identical to the filtration of the caffeine-containing solution except that it is performed with the control solution instead of the caffeine-containing protein solution.

2. The method of claim 1 , wherein the filtration process is a virus removal filtration process or an ultrafiltration/diafiltration process.

3. The method of claim 1 , wherein the improved parameter is the faster filtration rate than the filtration rate of the control solution.

4. The method of claim 1 , wherein the improved parameter is the production of a smaller amount of aggregated protein than the amount of aggregated protein produced by the control filtration process.

5. The method of claim 1 , wherein the improved filtration-related parameter is the higher mass transfer efficiency than the mass transfer efficiency of the control filtration process.

6. The method of claim 1 , wherein the improved parameter is the higher concentration or the higher yield of the protein than the concentration or yield of the protein produced by the control filtration process.

7. The method of claim 1 , wherein the viscosity-reducing amount is between about 1 mg/mL to about 22 mg/mL of the caffeine.

8. The method of claim 1 , wherein the carrier solution comprises an additional agent selected from the group consisting of preservatives, sugars, polysaccharides, arginine, proline, surfactants, stabilizers, and buffers.

9. The method of claim 1 , wherein the protein is a therapeutic protein.

10. The method of claim 9 , wherein the therapeutic protein is selected from the group consisting of a monoclonal antibody, a polyclonal antibody, an antibody fragment, a fusion protein, a PEGylated protein, an antibody-drug conjugate, a synthetic polypeptide, a protein fragment, a lipoprotein, an enzyme, and a structural peptide.

11. The method of claim 9 , wherein the therapeutic protein is a recombinant protein.

12. The method of claim 1 , further comprising a step of adding a second viscosity-reducing excipient to the carrier solution.

13. The method of claim 1 , wherein the viscosity-reducing amount is 30 mg/ml or less.

14. The method of claim 1 , wherein the viscosity-reducing amount is 22 mg/ml or less.

15. The method of claim 1 , wherein the viscosity-reducing amount is 15 mg/ml or less.

16. The method of claim 1 , wherein the filtration process is tangential flow filtration (TFF).

17. The method of claim 1 , wherein the filtration process is sterile filtration.

18. The method of claim 2 , wherein the filtration process is a virus removal filtration process.

19. The method of claim 18 , wherein the virus removal filtration process is nanofiltration.

20. The method of claim 2 , wherein the filtration process is an ultrafiltration/diafiltration process.

21. The method of claim 12 , wherein the second viscosity-reducing excipient is theophylline, tyramine, procaine, lidocaine, imidazole, aspartame, saccharin, and acesulfame potassium, niacinamide, and isonicotinamide.

Assignments (3)
CHANGE OF NAME Recorded Feb 16, 2022
From: REFORM BIOLOGICS, INC.
To: COMERA LIFE SCIENCES, INC.
Reel/Frame 059327/0985 →
CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jul 7, 2021
From: REFORM BIOLOGICS, LLC
To: REFORM BIOLOGICS, INC.
Reel/Frame 056784/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: SOANE, DAVID S.; WUTHRICH, PHILIP; MAHONEY, ROBERT P.; MOODY, MARK; GREENE, DANIEL G.; SCHAUER, NEIL L.
To: REFORM BIOLOGICS, LLC
Reel/Frame 045818/0611 →
Continuity (9)
Continuation In Part 15331197 · Oct 21, 2016
Continuation In Part 14966549 · Dec 11, 2015
Continuation In Part 14744847 · Jun 19, 2015
Provisional Application 62459893 · Feb 16, 2017
Provisional Application 62014784 · Jun 20, 2014
Provisional Application 62083623 · Nov 24, 2014
Provisional Application 62136763 · Mar 23, 2015
Provisional Application 62245513 · Oct 23, 2015
Related Publication 20190054175A1 · Feb 21, 2019